Differential distribution of linezolid in diseased and nondiseased bones in patients with spinal tuberculosis

BMC Infectious Diseases

Table 1 Clinical characteristics of the seven studied patients

Patient No.	Gender	Age (years)	Lesion site	BMI (kg/m²)	Dose/Weight (mg/kg)	HIV status	Comorbidity	Anti-TB treatment regimen
1	Female	30	L1-3	21.48	10.52	—^a	Pulmonary TB	H-Z-Lfx-Pto-Lzd
2	Male	45	T6-7	20.76	10.00	—^a	Pulmonary TB	H-R-E-Z-Lzd
3	Female	50	T10-11	25.24	9.52	—^a	— ^b	H-R-E-Z-Lzd
4	Male	17	L1-2	19.14	9.68	—^a	— ^b	H-R-E-Z-Lzd
5	Male	53	T8-9	20.76	10.00	—^a	Diabetes mellitus	H-R-E-Z-Lzd
6	Male	55	T10-11	20.31	11.54	—^a	Pulmonary TB	H-R-E-Z-Lzd
7	Male	39	T12-L1	20.37	9.09	—^a	Pulmonary TB	H-R-E-Z-Lzd
Median	—^b	45	—^b	20.76	10.00	—^b	—^b	—^b

No: number; T: thoracic vertebra; L: lumbar vertebra; BMI: body mass index; dose/weight: daily doses
of linezolid/patient’s weight; TB: tuberculosis; HIV: human immunodeficiency virus
^aNegative
^bNo data

ISSN: 1471-2334